Sequence Bio, a Newfoundland and Labrador-based genomics and discovery biology company, is proud to announce the appointment of Lynn Healey, CPA, CA as its Chief Executive Officer.
Lynn, an accomplished leader with a distinguished career in corporate and business development, strategic financial planning, risk management and organizational governance, transitions to the role of CEO from her former position as the company’s Chief Operating and Financial Officer. Prior to joining Sequence Bio, Lynn was the Chief Investment Officer of the Teachers’ Pension Plan Corporation in Newfoundland and Labrador, leading its investment and treasury functions. She is also a former Partner with EY, working from their Toronto and St. John’s offices.
"It is a privilege to lead Sequence Bio in its mission to accelerate the development of life-changing medicines,” said Lynn. “My focus is working with our incredibly passionate and talented team to help address global, unmet medical needs while continuing to advance our province's health innovation ecosystem and putting Newfoundlanders and Labradorians first every step of the way.”
In her prior role as Chief Operating and Financial Officer, Lynn oversaw all aspects of Sequence Bio’s finance, research, and human resources operations, and its Diversity, Equity, Inclusion, and Belonging (DEIB) program. She also directed the company’s volunteering and corporate giving initiatives, adding to her significant track record of community involvement alongside her current roles as a Director of the Cancer Care Foundation of NL, Newfoundland Power Inc., CPA NL, and as a Director and Treasurer of the 2025 Canada Games Host Society.
Mark Dobbin, Chair of the Board at Sequence Bio, noted, "Lynn is preceded by her reputation as a highly respected people and results-oriented executive. Her deep understanding of the company and communities in which it operates, coupled with her track record of success in international business, makes Lynn the ideal leader for Sequence Bio. On behalf of the Board of Directors, I would like to congratulate Lynn on her appointment to CEO and thank her for her dedication to the company and her team.”
Sequence Bio is a genomics and discovery biology company based in Newfoundland and Labrador, Canada. The company’s platform leverages Newfoundland’s founder effect to power discovery cohorts for novel target identification across disease indications of high unmet clinical need. Sequence Bio collaborates with the people of Newfoundland and Labrador and partners with the biopharma industry to help accelerate the development of new medicines for unmet medical needs across the globe.
VP, Market Development